Q3 2024 EPS Estimates for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Lifted by Leerink Partnrs

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at Leerink Partnrs lifted their Q3 2024 earnings per share estimates for Lexicon Pharmaceuticals in a research note issued on Tuesday, August 13th. Leerink Partnrs analyst R. Ruiz now anticipates that the biopharmaceutical company will post earnings per share of ($0.16) for the quarter, up from their previous estimate of ($0.18). Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.70) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.70) EPS, FY2025 earnings at ($0.55) EPS, FY2026 earnings at ($0.30) EPS and FY2027 earnings at $0.10 EPS.

A number of other equities research analysts also recently commented on LXRX. StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 9th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, May 3rd. Finally, SVB Leerink began coverage on Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They issued an “outperform” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.50.

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock opened at $1.66 on Friday. Lexicon Pharmaceuticals has a one year low of $0.92 and a one year high of $3.73. The company has a debt-to-equity ratio of 0.35, a quick ratio of 15.56 and a current ratio of 15.58. The company has a market cap of $408.75 million, a price-to-earnings ratio of -2.00 and a beta of 1.35. The business’s 50 day moving average price is $1.85 and its 200 day moving average price is $2.01.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative return on equity of 115.40% and a negative net margin of 5,509.34%. The firm had revenue of $1.65 million for the quarter, compared to the consensus estimate of $2.74 million. During the same quarter last year, the business posted ($0.22) earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in shares of Lexicon Pharmaceuticals by 82.6% in the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 26,859 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock valued at $15,363,000 after purchasing an additional 420,854 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 1st quarter valued at about $105,000. BVF Inc. IL lifted its holdings in shares of Lexicon Pharmaceuticals by 22.2% in the 4th quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after purchasing an additional 4,440,300 shares during the last quarter. Finally, Principal Securities Inc. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $33,000. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.